Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mills

Showing results (1201-1210 of 1,298) with videos related to

Pageof 130
Sort By:
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
Cell Reports|December 22, 2015
Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering GlycolysisRajesha Rupaimoole, Jaehyuk Lee, Monika Haemmerle, et al.
JAMA Oncology|July 17, 2015
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell CarcinomaEliezer M Van Allen, Vivian W Y Lui, Ann Marie Egloff, et al.
NPJ Precision Oncology|January 4, 2025
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancersDaehwan Kim, Heekyung Chung, Wen Liu, et al.
Nature Communications|July 14, 2022
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8<sup>+</sup> T-cell infiltration into tumorsLei Guan, Bin Wu, Ting Li, et al.
Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.
Nature Cell Biology|January 22, 2008
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradationJer-Yen Yang, Cong S Zong, Weiya Xia, et al.
Nature Genetics|April 2, 2024
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy responseZhe Hu, Zimeng Wu, Wei Liu, et al.
Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Pageof 130

Showing results (1201-1210 of 1,298) with videos related to

Sort By:
Pageof 130
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
Molecular Cancer Therapeutics|May 22, 2016
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics SystemFilip Janku, Helen J Huang, Bart Claes, et al.
Cell Reports|December 22, 2015
Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering GlycolysisRajesha Rupaimoole, Jaehyuk Lee, Monika Haemmerle, et al.
JAMA Oncology|July 17, 2015
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell CarcinomaEliezer M Van Allen, Vivian W Y Lui, Ann Marie Egloff, et al.
NPJ Precision Oncology|January 4, 2025
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancersDaehwan Kim, Heekyung Chung, Wen Liu, et al.
Nature Communications|July 14, 2022
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8<sup>+</sup> T-cell infiltration into tumorsLei Guan, Bin Wu, Ting Li, et al.
Molecular Cancer Therapeutics|August 31, 2016
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic MalignanciesGarrett W Rhyasen, Maureen M Hattersley, Yi Yao, et al.
Nature Cell Biology|January 22, 2008
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradationJer-Yen Yang, Cong S Zong, Weiya Xia, et al.
Nature Genetics|April 2, 2024
Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy responseZhe Hu, Zimeng Wu, Wei Liu, et al.
Nature Reviews. Cancer|September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Pageof 130